<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00206232</url>
  </required_header>
  <id_info>
    <org_study_id>H - 13988</org_study_id>
    <nct_id>NCT00206232</nct_id>
  </id_info>
  <brief_title>Novel Treatment for Diastolic Heart Failure in Women</brief_title>
  <official_title>Novel Treatment for Diastolic Heart Failure in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to collect information about the potential benefit and safety of
      low dose spironolactone for a patient with diastolic heart failure (DHF) and to determine
      whether spironolactone can cause the patient's condition to improve.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with diastolic heart failure defined based on clinical symptoms, echocardiography
      diastology parameters and brain natriuretic peptide level will be randomized in a 1:1 fashion
      to either placebo or spironolactone 25mg daily for 6 months. They will be assessed over this
      6 month period for improvement in exercise capacity, clinical symptoms, echocardiography
      diastology parameters, and biomarkers specific for heart failure. Safety of spironolactone in
      this patient population will also be assessed by recording adverse events and following
      electrolytes, blood urea nitrogen, and creatinine levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Six minute walk distance</measure>
    <time_frame>Baseline, then 3 and 6 months after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiography parameters of diastolic function</measure>
    <time_frame>Baseline, then 3 and 6 months after randomization</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Procollagen peptides, troponin I, tumor necrosis factor alpha, Brain Natriuretic Peptide</measure>
    <time_frame>Baseline then 3 and 6 months after randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Electrolytes, blood urea nitrogen, creatinine</measure>
    <time_frame>Screening and enrollment then 10 days, 4 weeks, 11 weeks, 13 weeks, and 15 weeks after randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life Questionaire</measure>
    <time_frame>Baseline, then 3 and 6 months after randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>New York Heart Association Classification</measure>
    <time_frame>Baseline then 3 and 6 months after randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From randomization until trial completion at 6 months.</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>Research subjects are randomized to placebo versus spironolactone 25mg daily and followed for 6 months.</description>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Aldactone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who are 18 years of age or older.

          -  Women with clinical heart failure for &gt; 2 months.

          -  Women with left ventricular ejection fraction &gt; 50% within 2 months of screening.

          -  Women with New York Heart Association class II or III heart failure symptoms.

          -  Brain Natriuretic Peptide &gt; 62 pg/ml within 2 months of screening.

          -  Patient on angiotensin converting enzyme inhibitor or angiotensin receptor blocker
             therapy for at least 1 month.

          -  Blood Pressure no more than 150/95.

          -  Patient able to walk more than 50 meters at the time of enrollment.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Current treatment with spironolactone.

          -  Severe hepatic impairment.

          -  Creatinine &gt; 2.5 mg/dl

          -  Potassium &gt; 5.0 mEq/L

          -  Intolerance to spironolactone in the past.

          -  Significant valvular heart disease, pericardial disease, or severe chronic lung
             disease with cor pulmonale.

          -  Unstable angina or myocardial infarction within the past 4 weeks.

          -  Severe peripheral vascular disease or other physical conditions that would limit the
             walking distance.

          -  Pregnant or lactating females.

          -  Participation in any other drug trial within 30 days prior to randomization.

          -  Inability to provide informed consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karla M Kurrelmeyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor College of Medicine Heart Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>February 15, 2013</last_update_submitted>
  <last_update_submitted_qc>February 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Karla Kurrelmeyer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Diastolic Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

